Monday, February 9, 1998
AxyS Pharmaceuticals Inc. published for the first time details
of its Delta technology, which had been described previously as a structure-based
drug design approach for finding specific potent protease inhibitors.
As published last week in Nature, the basis for Delta boils
down to the use of zinc ions to generate inhibitors with a higher affinity and
specificity for the active site of